Histones and lung cancer: are the histone deacetylases a promising therapeutic target? Vasiliki PettaIoannis GkiozosKonstantinos Syrigos Review Article 14 September 2013 Pages: 935 - 952
Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer Sook Ryun ParkYong Sang HongKyung Hae Jung Original Article 28 August 2013 Pages: 953 - 964
Evaluation of resveratrol sensitivities and metabolic patterns in human and rat glioblastoma cells Zheng SunShun ShiJia Liu Original Article 30 August 2013 Pages: 965 - 973
Adjuvant sequential chemoradiation therapy in high-risk endometrial cancer: results of a prospective, multicenter phase-II study of the NOGGO (North-Eastern German Society of Gynaecological Oncology) A. MusteaD. KoensgenG. Koehler Original Article 01 September 2013 Pages: 975 - 983
A retrospective study of S-1 and oxaliplatin combination chemotherapy in patients with refractory pancreatic cancer Naminatsu TakaharaHiroyuki IsayamaKazuhiko Koike Original Article 01 September 2013 Pages: 985 - 990
Physiologically based pharmacokinetic modelling of Busulfan: a new approach to describe and predict the pharmacokinetics in adults Christian DiestelhorstJoachim BoosGeorg Hempel Original Article 06 September 2013 Pages: 991 - 1000
Knockdown of cyclophilin A reverses paclitaxel resistance in human endometrial cancer cells via suppression of MAPK kinase pathways Zhengyu LiWenjiao MinJinhai Gou Original Article 14 September 2013 Pages: 1001 - 1011
Tumour tissue selectivity in the uptake and retention of SN 28049, a new topoisomerase II-directed anticancer agent Pradeep B. LukkaYing Yi ChenBruce C. Baguley Original Article 14 September 2013 Pages: 1013 - 1022
Serum epidermal growth factor is associated with prognosis and hormone receptor status in patients with HER2-positive metastatic breast cancer treated with first-line trastuzumab plus taxane chemotherapy Ji-Won KimJee Hyun KimIn Ae Park Original Article 15 September 2013 Pages: 1023 - 1029
DCA increases the antitumor effects of capecitabine in a mouse B16 melanoma allograft and a human non-small cell lung cancer A549 xenograft Mao-fa ZhengSi-yu ShenWei-da Huang Original Article 17 September 2013 Pages: 1031 - 1041
Phase I study of the safety, pharmacokinetics and antitumor activity of famitinib Aiping ZhouWen ZhangJinwan Wang Original Article 17 September 2013 Pages: 1043 - 1053
Changes in fPSA level could discriminate tPSA flare-up from tPSA progression in patients with castration-refractory prostate cancer during the initial phase of docetaxel-based chemotherapy Jun DuQing YangXin Yao Original Article 17 September 2013 Pages: 1055 - 1061
A phase I, pharmacokinetic and pharmacodynamic study of nimotuzumab in Japanese patients with advanced solid tumors Wataru OkamotoTakayuki YoshinoKazuhiko Nakagawa Original Article 18 September 2013 Pages: 1063 - 1071
A phase I and pharmacokinetic study of oxaliplatin and bortezomib: activity, but dose-limiting neurotoxicity B. KobrinskyS. O. JosephH. Hochster Original Article 19 September 2013 Pages: 1073 - 1078
Comparative pharmacokinetics of subcutaneous trastuzumab administered via handheld syringe or proprietary single-use injection device in healthy males Chris J. WynneRod B. Ellis-PeglerBert L. Lum Original Article 22 September 2013 Pages: 1079 - 1087
Phase I study evaluating the combination of lapatinib (a Her2/Neu and EGFR inhibitor) and everolimus (an mTOR inhibitor) in patients with advanced cancers: South West Oncology Group (SWOG) Study S0528 Shirish M. GadgeelDanika L. LewRazelle Kurzrock Original Article 22 September 2013 Pages: 1089 - 1096
FOLFIRI plus bevacizumab as a first-line treatment for Japanese patients with metastatic colorectal cancer: a JACCRO CC-03 multicenter phase II study Mitsugu KochiYuji AkiyamaToshifusa Nakajima Original Article 22 September 2013 Pages: 1097 - 1102
A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC) Luis E. RaezEdgardo S. SantosBarrett H. Childs Original Article 22 September 2013 Pages: 1103 - 1110
Circadian variability of pharmacokinetics of cisplatin in patients with non-small-cell lung carcinoma: analysis with the NONMEM program Rong ChenJie LiLi-yan Miao Original Article 24 September 2013 Pages: 1111 - 1123
Expression of thymidylate synthase predicts clinical outcomes of pemetrexed-containing chemotherapy for non-small-cell lung cancer: a systemic review and meta-analysis Yu LiuTie-Jun YinRong-Ge Zhang Original Article 26 September 2013 Pages: 1125 - 1132
Exposure–response analysis of pertuzumab in HER2-positive metastatic breast cancer: absence of effect on QTc prolongation and other ECG parameters Amit GargJing LiBert Lum Clinical Trial Report Open access 03 September 2013 Pages: 1133 - 1141
Calcium carbonate does not affect nilotinib pharmacokinetics in healthy volunteers Hussein A. TawbiAn L. TranJan H. Beumer Short Communication 14 September 2013 Pages: 1143 - 1147
Population pharmacokinetics of dimethylacetamide in children during standard and once-daily IV busulfan administration Mirjam N. TrameImke H. BartelinkGeorg Hempel Short Communication 15 September 2013 Pages: 1149 - 1155
